NASDAQ:ACST

Acasti Pharma - ACST Stock Forecast, Price & News

$0.96

+0.05 (+5.52%)

(As of 08/12/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.88
▼
$0.96
50-Day Range: $0.80
▼
$1.02
52-Week Range: $0.80
▼
$3.86

Volume: 161,696 shs
Average Volume: 80,578 shs
Market Capitalization: $42.49 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

Acasti Pharma MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 528.3% Upside
$6.00 Price Target
Short Interest: Healthy
0.89% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.21
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.62) to ($0.50) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

371st out of 1,117 stocks

Pharmaceutical Preparations Industry

183rd out of 550 stocks

3.5

Analyst's Opinion

Consensus Rating
Acasti Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, Acasti Pharma has a forecasted upside of 528.3% from its current price of $0.96.
Amount of Analyst Coverage
Acasti Pharma has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.89% of the float of Acasti Pharma has been sold short.
Short Interest Ratio / Days to Cover
Acasti Pharma has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Acasti Pharma has recently decreased by 13.65%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Acasti Pharma does not currently pay a dividend.
Dividend Growth
Acasti Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACST.

2.9

News and Social Media Coverage

News Sentiment
Acasti Pharma has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Acasti Pharma this week, compared to 0 articles on an average week.
Search Interest
Only 2 people have searched for ACST on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Acasti Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Acasti Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.70% of the stock of Acasti Pharma is held by insiders.
Percentage Held by Institutions
Only 0.46% of the stock of Acasti Pharma is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Acasti Pharma are expected to grow in the coming year, from ($0.62) to ($0.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Acasti Pharma is -4.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Acasti Pharma is -4.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Acasti Pharma has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Acasti Pharma (NASDAQ:ACST) Stock

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Acasti Pharma Stock Performance

Shares of Acasti Pharma stock traded up $0.05 during trading hours on Friday, hitting $0.96. The company's stock had a trading volume of 161,696 shares, compared to its average volume of 80,578. The firm has a fifty day moving average of $0.89 and a 200-day moving average of $1.02. The stock has a market cap of $42.49 million, a price-to-earnings ratio of -4.77 and a beta of 1.67. Acasti Pharma has a twelve month low of $0.80 and a twelve month high of $3.86.

Acasti Pharma (NASDAQ:ACST - Get Rating) last posted its earnings results on Tuesday, June 21st. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.09. On average, sell-side analysts expect that Acasti Pharma will post -0.62 earnings per share for the current fiscal year.

Receive ACST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter.

ACST Stock News Headlines

August 11, 2022 | seekingalpha.com

Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q1 2023 Results - Earnings Call Transcript

August 9, 2022 | americanbankingnews.com

Acasti Pharma (ACST) to Release Earnings on Thursday

August 2, 2022 | finance.yahoo.com

Acasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022

July 31, 2022 | americanbankingnews.com

Short Interest in Acasti Pharma Inc. (NASDAQ:ACST) Declines By 58.1%

June 21, 2022 | finance.yahoo.com

Acasti Pharma Reports Fiscal Year 2022 Operational Results

June 16, 2022 | finance.yahoo.com

Acasti Pharma Schedules Fiscal Year 2022 Business Update Conference Call

June 14, 2022 | seekingalpha.com

Acasti gets patents related to brain hemorrhage drug GTX-104, pain therapy GTX-101

June 14, 2022 | finance.yahoo.com

Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101

May 18, 2022 | finance.yahoo.com

Acasti Pharma's IV Hemorrhage Drug Candidate At Par With Oral Nimodipine

May 18, 2022 | seekingalpha.com

Acasti says pharmacokinetic trial for lead asset met all study goals

May 18, 2022 | finance.yahoo.com

Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints

May 16, 2022 | finanznachrichten.de

Acasti Pharma Inc.: Update: Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 18th

May 16, 2022 | finance.yahoo.com

Update: Acasti Pharma CEO to Present at Microcap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 18th

May 12, 2022 | finanznachrichten.de

Acasti Pharma Inc.: Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16th

May 12, 2022 | finance.yahoo.com

Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16th

April 25, 2022 | finance.yahoo.com

Acasti Pharma to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28th

February 28, 2022 | finance.yahoo.com

Acasti Pharma Celebrates Rare Disease Day

February 22, 2022 | finance.yahoo.com

Acasti Pharma Inc. CEO, Jan D'Alvise, Is Featured on The Stock Day Podcast

February 14, 2022 | finance.yahoo.com

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2022

December 31, 2021 | finance.yahoo.com

BLITF Stock: 7 Thing to Know About Mobile Gaming Play i3 Interactive as Shares Rocket Today

December 23, 2021 | benzinga.com

Thinking about buying stock in SeaChange International, American Virtual Cloud Technologies, Quoin Pharmaceuticals, Acasti Pharma, or CohBar?

December 22, 2021 | markets.businessinsider.com

See Why Acasti Pharma Shares Are Trading Over 20% Higher?

December 21, 2021 | finance.yahoo.com

Market Sentiment Around Loss-Making Acasti Pharma Inc. (CVE:ACST)

December 2, 2021 | finance.yahoo.com

Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104

November 12, 2021 | finance.yahoo.com

Acasti Pharma Announces Annual Stock Option Grants

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ACST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter.

ACST Company Calendar

Last Earnings: 6/21/2022
Today: 8/13/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 3/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ACST
CUSIP: N/A
CIK: 1444192
Web: www.acastipharma.com
Phone: 45-0686-4555
Fax: 45-0687-2272
Employees: 32
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.00
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +528.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-9,820,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -10.10%
Return on Assets: -9.29%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 13.97
Quick Ratio: 13.97

Sales & Book Value

Annual Sales: $200,000.00
Price / Sales: 212.44
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.44 per share
Price / Book: 0.39

Miscellaneous

Outstanding Shares: 44,490,000
Free Float: 42,848,000
Market Cap: $42.49 million
Optionable: Not Optionable
Beta: 1.67

Key Executives

Ms. Janelle D'Alvise (Age 66)
Pres, CEO, Corp. Sec. & Director
Comp: $428.04k
Dr. Pierre Lemieux M.D. (Age 57)
Ph.D., Co-Founder, COO & Chief Scientific Officer
Comp: $276.38k
Mr. Brian D. Ford CPA (Age 63)
CA, Chief Financial Officer
Comp: $364.82k
Dr. Yves Lachance Ph.D.
VP of Quality & Compliance
Ms. Christine Pelletier
Sr. Director of HR
Dr. George Kottayil
Chief Operating Officer of US
Mr. Prashant Kohli
VP of Commercial Operations

Key Competitors

View All Competitors

Insiders & Institutions

Bank of America Corp DE
Bought 35,962 shares on 6/7/2022
Ownership: 0.128%

View All Insider Transactions
View All Institutional Transactions

ACST Stock - Frequently Asked Questions

Should I buy or sell Acasti Pharma stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACST shares.
View ACST analyst ratings or view top-rated stocks.
What is Acasti Pharma's stock price forecast for 2022?: 1 analysts have issued 1-year target prices for Acasti Pharma's stock. Their ACST share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 528.3% from the stock's current price.
View analysts price targets for ACST or view top-rated stocks among Wall Street analysts.
How have ACST shares performed in 2022?: Acasti Pharma's stock was trading at $1.26 at the start of the year. Since then, ACST shares have decreased by 24.2% and is now trading at $0.9550.
View the best growth stocks for 2022 here.
When is Acasti Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our ACST earnings forecast.
How were Acasti Pharma's earnings last quarter?: Acasti Pharma Inc. (NASDAQ:ACST) issued its earnings results on Tuesday, June, 21st. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.09.

When did Acasti Pharma's stock split?: Acasti Pharma's stock reverse split on Tuesday, August 31st 2021. The 1-8 reverse split was announced on Tuesday, August 31st 2021. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 31st 2021. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.
What other stocks do shareholders of Acasti Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB), SCYNEXIS (SCYX), Outlook Therapeutics (OTLK), Bionano Genomics (BNGO), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Heat Biologics (HTBX), KushCo (KSHB), Miragen Therapeutics (MGEN) and Aeterna Zentaris (AEZS).
What is Acasti Pharma's stock symbol?: Acasti Pharma trades on the NASDAQ under the ticker symbol "ACST."
How do I buy shares of Acasti Pharma?: Shares of ACST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Acasti Pharma's stock price today?: One share of ACST stock can currently be purchased for approximately $0.96.
How much money does Acasti Pharma make?: Acasti Pharma (NASDAQ:ACST) has a market capitalization of $42.49 million and generates $200,000.00 in revenue each year. The biopharmaceutical company earns $-9,820,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis.
How can I contact Acasti Pharma?: Acasti Pharma's mailing address is 3009 BOUL. DE LA CONCORDE EAST SUITE 102, LAVAL A8, H7E 2B5. The official website for the company is www.acastipharma.com. The biopharmaceutical company can be reached via phone at 45-0686-4555, via email at acst@crescendo-ir.com, or via fax at 45-0687-2272.

This page (NASDAQ:ACST) was last updated on 8/13/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Acasti Pharma - ACST Stock Forecast, Price & News

Acasti Pharma MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Acasti Pharma (NASDAQ:ACST) Stock

Acasti Pharma Stock Performance

ACST Stock News Headlines

ACST Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ACST Stock - Frequently Asked Questions

Should I buy or sell Acasti Pharma stock right now?

What is Acasti Pharma's stock price forecast for 2022?

How have ACST shares performed in 2022?

When is Acasti Pharma's next earnings date?

How were Acasti Pharma's earnings last quarter?

When did Acasti Pharma's stock split?

What other stocks do shareholders of Acasti Pharma own?

What is Acasti Pharma's stock symbol?

How do I buy shares of Acasti Pharma?

What is Acasti Pharma's stock price today?

How much money does Acasti Pharma make?

How can I contact Acasti Pharma?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™